Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205127982> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4205127982 endingPage "328" @default.
- W4205127982 startingPage "328" @default.
- W4205127982 abstract "328 Background: ESCC is a health burden in Taiwan due to smoking and drinking habits. In R/M setting, the prognosis is worse. In 2021, KN590 study(pembrolizumab with chemotherapy in CPS≥10%), CM648 study(nivolumab with chemotherapy or nivolumab with ipilimumab in TPS≥1%), and ESCORt-1st study(camrelizumab with chemotherapy in TPS≥1%) have all been shown to get survival benefits compared with chemotherapy alone in front-line setting. Further immunotherapy combinations with targeted therapies and subsequent therapy options after anti-PD1 failure deserve more investigation. Methods: From early 2016 to late 2021, 26 advanced ESCC patients had ever received immunotherapy-containing regimens in Yun-lin Branch of National Taiwan University Hospital. We have reviewed basic characters, ICIs regimens, and treatment response of these patients. Results: 3 patients under progression during front-line KN590 got PR by subsequent afatinib(2) or lenvatinib(1) use. So, the overall response rate of advanced ESCC to immunotherapy-containing regimens was 59%(17/29) and disease control rate was 72%(21/29). Conclusions: Afatinib has multiple immuno-modulatory effects. AP or NA is an effective regimen in Taiwan, where double cancers, like HNSCC and ESCC, are popular due to smoking, drinking, and bêtel-nuts chewing. Following KN590 good efficacy was also seen in our institution and afatinib with anti-PD1 could be introduced in CT-unfit patients. In unresectable and/or oligometastatic ESCC, induction triple therapy may lead to conversion chemoradiation, even to final surgery. EGFR or VEGFR TKI with immunotherapy might also be a subsequent recue regimen after front-line anti-PD1 failure.[Table: see text]" @default.
- W4205127982 created "2022-01-26" @default.
- W4205127982 creator A5004087911 @default.
- W4205127982 creator A5015847499 @default.
- W4205127982 creator A5029120675 @default.
- W4205127982 creator A5030139791 @default.
- W4205127982 creator A5053316607 @default.
- W4205127982 creator A5069207418 @default.
- W4205127982 creator A5076979086 @default.
- W4205127982 date "2022-02-01" @default.
- W4205127982 modified "2023-09-27" @default.
- W4205127982 title "Multiple combinational strategies of immunotherapy for esophageal squamous cell carcinoma: One institutional experience in Taiwan since 2016." @default.
- W4205127982 doi "https://doi.org/10.1200/jco.2022.40.4_suppl.328" @default.
- W4205127982 hasPublicationYear "2022" @default.
- W4205127982 type Work @default.
- W4205127982 citedByCount "0" @default.
- W4205127982 crossrefType "journal-article" @default.
- W4205127982 hasAuthorship W4205127982A5004087911 @default.
- W4205127982 hasAuthorship W4205127982A5015847499 @default.
- W4205127982 hasAuthorship W4205127982A5029120675 @default.
- W4205127982 hasAuthorship W4205127982A5030139791 @default.
- W4205127982 hasAuthorship W4205127982A5053316607 @default.
- W4205127982 hasAuthorship W4205127982A5069207418 @default.
- W4205127982 hasAuthorship W4205127982A5076979086 @default.
- W4205127982 hasConcept C121608353 @default.
- W4205127982 hasConcept C126322002 @default.
- W4205127982 hasConcept C143998085 @default.
- W4205127982 hasConcept C2776694085 @default.
- W4205127982 hasConcept C2777701055 @default.
- W4205127982 hasConcept C2778087573 @default.
- W4205127982 hasConcept C2779438470 @default.
- W4205127982 hasConcept C2780030458 @default.
- W4205127982 hasConcept C2780057760 @default.
- W4205127982 hasConcept C2780586478 @default.
- W4205127982 hasConcept C2781413609 @default.
- W4205127982 hasConcept C2781433595 @default.
- W4205127982 hasConcept C71924100 @default.
- W4205127982 hasConceptScore W4205127982C121608353 @default.
- W4205127982 hasConceptScore W4205127982C126322002 @default.
- W4205127982 hasConceptScore W4205127982C143998085 @default.
- W4205127982 hasConceptScore W4205127982C2776694085 @default.
- W4205127982 hasConceptScore W4205127982C2777701055 @default.
- W4205127982 hasConceptScore W4205127982C2778087573 @default.
- W4205127982 hasConceptScore W4205127982C2779438470 @default.
- W4205127982 hasConceptScore W4205127982C2780030458 @default.
- W4205127982 hasConceptScore W4205127982C2780057760 @default.
- W4205127982 hasConceptScore W4205127982C2780586478 @default.
- W4205127982 hasConceptScore W4205127982C2781413609 @default.
- W4205127982 hasConceptScore W4205127982C2781433595 @default.
- W4205127982 hasConceptScore W4205127982C71924100 @default.
- W4205127982 hasIssue "4_suppl" @default.
- W4205127982 hasLocation W42051279821 @default.
- W4205127982 hasOpenAccess W4205127982 @default.
- W4205127982 hasPrimaryLocation W42051279821 @default.
- W4205127982 hasRelatedWork W16012415 @default.
- W4205127982 hasRelatedWork W1852032 @default.
- W4205127982 hasRelatedWork W2293350 @default.
- W4205127982 hasRelatedWork W2516816 @default.
- W4205127982 hasRelatedWork W3079368 @default.
- W4205127982 hasRelatedWork W3198621 @default.
- W4205127982 hasRelatedWork W343746 @default.
- W4205127982 hasRelatedWork W370487 @default.
- W4205127982 hasRelatedWork W4787500 @default.
- W4205127982 hasRelatedWork W5038423 @default.
- W4205127982 hasVolume "40" @default.
- W4205127982 isParatext "false" @default.
- W4205127982 isRetracted "false" @default.
- W4205127982 workType "article" @default.